Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Completed
Bristol-Myers Squibb
Phase 2
2001-03-01
The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is
as efficacious as treatment with cyclosporine at preventing acute rejection and with a
superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid
problems, less diabetes mellitus).
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
Completed
Bristol-Myers Squibb
Phase 3
2005-02-01
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of
immunosuppression treatment in patients undergoing a renal transplant where the donor kidney
is obtained in patients with extended criteria.
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)
Completed
Bristol-Myers Squibb
Phase 3
2005-03-01
The purpose of this study is to learn if Belatacept can provide protection from organ
rejection following kidney transplantation while avoiding some of the toxic effects of
standard immunosuppressive medications such as kidney damage. Effects on kidney function and
patient survival as well as drug safety will also be studied.
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a
part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a
part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
Completed
Bristol-Myers Squibb
Phase 1/Phase 2
1969-12-31
This randomized, double-blind, placebo controlled, parallel and multiple dose study provided
safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and
BMS-224818 in subjects with RA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
